1. A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. (October 2018) Authors: Yerushalmi, Rinat; Eiermann, Wolfgang; Rugo, Hope; Ettl, Johannes; Hurvitz, Sara A.; Gonçalves, Anthony; Miguel, Martin; Markova, Denka; Tudor, Iulia; Blum, Joanne; Hannah, Alison; Litton, Jennifer Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting. (3rd September 2015) Authors: Hesketh, Paul J.; Aapro, Matti; Jordan, Karin; Schwartzberg, Lee; Bosnjak, Snezana; Rugo, Hope Other Names: Li Min Academic Editor. Journal: BioMed research international Issue: Volume 2015(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. (28th March 2022) Authors: Borno, Hala T; Kim, Mi-Ok; Hong, Julian C; Yousefi, Sasha; Lin, Amy; Tolstykh, Irina; Zhang, Sylvia; McKay, Rana R; Harismendy, Olivier; Cinar, Pelin; Rugo, Hope; Koshkin, Vadim S; Rabow, Maya; Wang, Christine; Bailey, Adina; Small, Eric J Journal: Oncologist Issue: Volume 27:Number 5(2022) Page Start: 398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. Issue 4 (May 2022) Authors: Peil, Elizabeth; Williams, Grant R.; Rugo, Hope; Woyach, Jennifer A.; Jatoi, Aminah; Le-Rademacher, Jennifer G. Journal: Journal of geriatric oncology Issue: Volume 13:Issue 4(2022) Page Start: 526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. (October 2018) Authors: Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope; Castrellon, Aurelio; Joy, Anyl A.; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; Loibl, Sibylle; Finn, Richard S. Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?. (August 2022) Authors: Corti, Chiara; Antonarelli, Gabriele; Valenza, Carmine; Nicolò, Eleonora; Rugo, Hope; Cortés, Javier; Harbeck, Nadia; Carey, Lisa A.; Criscitiello, Carmen; Curigliano, Giuseppe Journal: European journal of cancer Issue: Volume 171(2022) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation. (October 2018) Authors: Hurvitz, Sara A.; Quek, Ruben G.W.; Ettl, Johannes; Rugo, Hope; Bhattacharyya, Helen; Hannah, Alison L.; Litton, Jennifer Keating Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PO112EFFICACY OF NEPA, THE FIRST COMBINATION ANTIEMETIC AGENT, IN PATIENTS WITH BREAST CANCER RECEIVING ANTHRACYCLINE/CYCLOPHOSPHAMIDE (AC) OR NON-AC CHEMOTHERAPY. (November 2015) Authors: Rugo, Hope; Aapro, Matti; Rossi, Giorgia; Rizzi, Giada Journal: Breast Issue: Volume 24(2015)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. (10th July 2021) Authors: Spring, Laura M.; Nakajima, Erika; Hutchinson, Jennifer; Viscosi, Elene; Blouin, Gayle; Weekes, Colin; Rugo, Hope; Moy, Beverly; Bardia, Aditya Journal: Oncologist Issue: Volume 26:Number 10(2021) Page Start: 827 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Sacituzumab Govitecan for Metastatic Triple‐Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. (10th July 2021) Authors: Spring, Laura M.; Nakajima, Erika; Hutchinson, Jennifer; Viscosi, Elene; Blouin, Gayle; Weekes, Colin; Rugo, Hope; Moy, Beverly; Bardia, Aditya Journal: Oncologist Issue: Volume 26:Number 10(2021) Page Start: 827 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗